Editor's Note: In less than a year, Oxford Club Chief Trends Strategist Matthew Carr's two best stocks went up 586% and 316%. But only 455 people were signed up to receive the alerts on these companies. Matthew wants to make sure that no one misses these kinds of gains again... So he is giving away one FREE bonus year of access to his record-setting Trailblazer Pro research service. Normally, this service costs $4,000 for a single year... so you'll want to take advantage of this! Click here to claim this offer now. - Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance
"Don't let news negativity fool you. The average investor can beat the market." Matthew Carr, Chief Trends Strategist, The Oxford Club Wall Street money managers LOVE to say, "Regular investors can't beat the market." I get it. That statement helps justify their jobs. They sing this as gospel, despite the unsettling fact that 90% of professional money jockeys can't beat the market. I mean, logically, if their full-time job is devoted to outperforming the market, and they can't do it, then how can a retail investor - who's only a part-time trader - hope to accomplish it? Of course, the mainstream media doesn't get it either. There are articles that make my blood boil, like the one I saw years ago on CBS News titled "You Can't Beat the Market, So Stop Trying." Or what I think is the worst advice - though I've seen it countless times - "Hunker down in bonds and savings accounts." Savings accounts?! I'd rather take an America's Funniest Home Videos-worthy shot to the family jewels! And considering the potential prize money, that might have a more profound impact on my retirement. Picking Out the Bad Apples Oftentimes, the only course of action is to ignore the talking heads. Especially when they start speaking out of both sides of their mouths. Though, as investors, we're subject to the volatility that the words falling from their lips cause. Let's take COVID-19 vaccine maker Moderna (Nasdaq: MRNA) as a prime example. In mid-August, shares trailed lower over value concerns. And this move added to the steep drop they endured after hitting all-time highs earlier in the month. Now, a 24.5% dip isn't something we can easily wave off, like a sudden, unpleasant smell. But Moderna has outperformed the S&P 500 by an astronomical amount in 2021. In fact, the index's 22% gain appears as a nearly horizontal line next to Moderna's 259% run. And keep in mind that Moderna shares skyrocketed 434% in 2020. The issue analysts are having is that their consensus price target for the vaccine maker is $295.83. Even after the recent pullback, shares would still need to fall another 21% to come in line with that level. Here's the deal... From Wall Street's perspective, Moderna is one of 70 companies in the S&P 500 that analysts consider overvalued. GASP! That seems like a lot. But in reality, it's only about 14% of the index. If 14% of an apple has a bruise, you simply avoid that part and eat around it. The other 86% is good. And for the S&P 500, that's about 430 companies. That's a buffet for retail investors to feast on! | 
没有评论:
发表评论